Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Abivax logo — company profile

Abivax

Founded 2013 France France 90 employees Post-IPO Debt Total: $376.20M Biotechnology, Health Care +1

General Information

Company Name Abivax
Founded Year 2013
Location France France
Founders / Decision Makers
Team member Team member
Employees 90
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Abivax. To contact Abivax, visit abivax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

In The News Sep 07, 2026

Featured on Eu-startups: London’s Claret Capital Partners closes Fund IV at €575 million to back European...

Get alerts when Abivax shows new signals

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Additionally, Abivax plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which is believed to have the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers. Founded in 2013 and headquartered in France, Abivax received a €150.00M Post-IPO Debt investment on 21 August 2023 from Claret Capital, Kreos Capital, and Heights Capital Management. The company operates in the Biotechnology, Health Care, and Health and Wellness industries. This strategic investment is expected to support the advancement of their innovative therapies and further solidify their position in the biotechnology sector.

Services & Products

Development and clinical testing of novel small molecule drugs targeting chronic inflammatory diseases

Target Customers

Patients with chronic inflammatory diseases healthcare professionals pharmaceutical companies investors

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt €150.00M 3
Claret Capital Kreos Capital
Claret Capital, Kreos Capital +1
21 Aug 2023
Post IPO Equity €130.00M 10
Sofinnova Partners Boxer Capital Invus
Sofinnova Partners, Boxer Capital +8
22 Feb 2023
Post IPO Equity €49.20M 6
Sofinnova Partners Invus Deep Track Capital
Sofinnova Partners, Invus +4
02 Sep 2022
Post IPO Debt €15.00M 1
Kreos Capital
Kreos Capital
13 Oct 2020
Post IPO Equity €12.00M 1
Sofinnova Partners
Sofinnova Partners
12 Jul 2019
Post IPO Debt €20.00M 1
Kreos Capital
Kreos Capital
25 Jul 2018

Latest News

View All
London’s Claret Capital Partners closes Fund IV at €575 million to back European tech, life sciences... — Eu-startups
London’s Claret Capital Partners closes Fund IV at €575 million to back European tech, life sciences and impact companies
Eu-startups Sep 07, 2026

Abivax Alternatives & Competitors

View All Alternatives
Abivax vs
Finch Therapeutics
Finch Therapeutics

Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigation...

Series D
20 employees
Biotechnology, Health and Wellness
Abivax vs
Topivert Pharma Limited
Topivert Pharma Limited United Kingdom

TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinas...

Series A
3 employees
Biotechnology, Health Care
Abivax vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 cl...
Abivax was founded in 2013.
Abivax is headquartered in France.
Abivax operates in Biotechnology, Health Care and Health and Wellness. Its customers include Patients with chronic inflammatory diseases, healthcare professionals and pharmaceutical companies.
Abivax has approximately 90 employees.
Abivax has completed 6 funding rounds, raising a total of $376.20M. The latest funding stage is Post-IPO Debt.
Abivax offers: Development and clinical testing of novel small molecule drugs targeting chronic inflammatory diseases.
Top alternatives and competitors to Abivax include Finch Therapeutics, Topivert Pharma Limited, Entero Therapeutics (Nasdaq: ENTO), Applied Molecular Transport, Immune Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Abivax and Finch Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Abivax, https://bouncewatch.com/company/abivax, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes